• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Equity Performance Group Issues Investment Profile on Aida Pharmaceuticals

Posted on: Wednesday, 21 June 2006, 09:00 CDT

HANGZHOU, China, June 21 /PRNewswire/ -- Aida Pharmaceuticals, Inc. (BULLETIN BOARD: AIDA) , one of mainland China's leading pharmaceutical companies, announced today that Equity Performance Group has issued an Investment Profile on Aida Pharmaceuticals.

The Investment Profile is a comprehensive corporate summary of Aida Pharmaceuticals, the Company's business model and the Chinese pharmaceutical market. The report also includes investment catalysts and recent news. The following are excerpts from the Investment Profile:

"Aida Pharmaceuticals develops, manufactures and markets pharmaceuticals, primarily in mainland China....Aida holds the exclusive patent on the powder and transfusion form of Etimicin Sulfate through 2012 and is one of two exclusive producers of its liquid form. Aida has seven additional pipeline drugs in advanced stages of development: three gene therapy cancer drugs including patented Rh-Apo2l nearing the end of phase I trials, Prodigiosin for treating pancreatic cancer, Anti-CD86 monoclonal anti-body for the treatment of immunity-related diseases, Anti-CTLA-4 monoclonal anti-body for the treatment of tumors and stroke recovery medicine SYO2....Aida Pharmaceuticals recently reported $5.33 million in revenues for the first quarter of 2006. Previously, the Company reported an $8.8 million increase in annual revenues from $15.65 million in 2004 to $24.53 million in 2005 and the Company expects an annual revenue growth rate of about 30% through the next five years."

To view the complete Investment Profile and for full disclosure terms, please visit http://equityperfgp.com/_wsn/page14.html.

About Equity Performance Group

The Equity Performance Group provides publicly traded micro-cap companies with services to enhance their trading performance. The Company's advisory services and proactive campaigns are custom designed to dramatically improve each client's exposure by communicating financial catalysts; transition and turnaround strategies; and breaking news to a broad retail and institutional audience within the financial community. Improved trading performance and an expanding shareholder base facilitates capital raises, secondary offerings, merger and acquisition activity, float diversification, and can ensure that listing/exchange requirements are continuously met.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically- friendly practices. Aida is now producing and marketing a patented prescription drug in China, Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category "A" drug by the State Food and Drug Administration of China.

Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 Investor Relations: Equity Performance Group Gary Geraci (617) 723-2373 gary@equityperfgp.com

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:

This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations are detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov/.

Equity Performance Group

CONTACT: Gary Geraci, Investor Relations of Equity Performance Group,+1-617-723-2373, gary@equityperfgp.com

Web site: http://equityperfgp.com/_wsn/page14.html

Source: PRNewswire

More News in this Category